Flavonols as a Potential Pharmacological Intervention for Alleviating Cognitive Decline in Diabetes: Evidence from

Anđela Horvat1, Ignacija Vlašić1, Jasminka Štefulj2,3

  • 1Division of Molecular Medicine, Ruđer Bošković Institute, Bijenička 54, 10000 Zagreb, Croatia.

Life (Basel, Switzerland)
|December 23, 2023
PubMed

Insights

Flavonols, found in many foods, show promise in protecting against diabetes-related cognitive decline by reducing inflammation and oxidative stress. Further human studies are needed to confirm these neuroprotective effects in diabetic patients.

Area of Science:

  • Neuroscience
  • Metabolic Diseases
  • Nutritional Science

Background:

  • Diabetes mellitus is linked to cognitive impairment, including hippocampal atrophy and reduced synaptic plasticity.
  • Pathological mechanisms include advanced glycation end products (AGEs), oxidative stress, neuroinflammation (NF-κB), reduced brain-derived neurotrophic factor (BDNF), and disrupted neuronal signaling.
  • Dietary interventions are increasingly recognized for preventing diabetic complications.

Purpose of the Study:

  • To review molecular mechanisms of diabetes-induced cognitive dysfunction.
  • To summarize preclinical evidence on flavonols' neuroprotective effects against cognitive decline in diabetes.

Main Methods:

  • Review of preclinical studies on flavonols and diabetes-related cognitive impairment.
  • Analysis of molecular pathways affected by diabetes and modulated by flavonols.

Main Results:

  • Flavonols exhibit neuroprotective, antioxidative, anti-inflammatory, and memory-enhancing properties in preclinical models.
  • They regulate glucose, attenuate oxidative stress and inflammation, promote neurotrophic factors, and modulate neuronal signaling pathways.
  • Flavonols demonstrate potential in alleviating cognitive impairment in diabetes.

Conclusions:

  • Flavonols show significant potential as a dietary intervention for mitigating diabetes-associated cognitive decline.
  • Preclinical findings are promising, but further clinical and epidemiological research is essential to validate these benefits in diabetic patients.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
944
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
179
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K